211 related articles for article (PubMed ID: 11595726)
81. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1).
Sugimoto M; Nakamura T; Ohtani N; Hampson L; Hampson IN; Shimamoto A; Furuichi Y; Okumura K; Niwa S; Taya Y; Hara E
Genes Dev; 1999 Nov; 13(22):3027-33. PubMed ID: 10580009
[TBL] [Abstract][Full Text] [Related]
82. Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice.
Hacker E; Muller HK; Irwin N; Gabrielli B; Lincoln D; Pavey S; Powell MB; Malumbres M; Barbacid M; Hayward N; Walker G
Cancer Res; 2006 Mar; 66(6):2946-52. PubMed ID: 16540642
[TBL] [Abstract][Full Text] [Related]
83. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence.
Rane SG; Cosenza SC; Mettus RV; Reddy EP
Mol Cell Biol; 2002 Jan; 22(2):644-56. PubMed ID: 11756559
[TBL] [Abstract][Full Text] [Related]
84. Cell cycle control as a promising target in melanoma.
Lee B; Sandhu S; McArthur G
Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
[TBL] [Abstract][Full Text] [Related]
85. The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.
Al-Khalaf HH; Mohideen P; Nallar SC; Kalvakolanu DV; Aboussekhra A
J Biol Chem; 2013 Dec; 288(49):35511-25. PubMed ID: 24163379
[TBL] [Abstract][Full Text] [Related]
86. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
Jiao Y; Feng Y; Wang X
Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
[TBL] [Abstract][Full Text] [Related]
87. Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
Shannon JA; Matias C; Luxford C; Kefford RF; Mann GJ
Melanoma Res; 1999 Apr; 9(2):133-7. PubMed ID: 10380935
[TBL] [Abstract][Full Text] [Related]
88. Forced expression of the cyclin-dependent kinase inhibitor p16(INK4A) in leukemic U-937 cells reveals dissociation between cell cycle and differentiation.
Bergh G; Telleus A; Fritzon A; Kornfält S; Johnson E; Olsson I; Gullberg U
Exp Hematol; 2001 Dec; 29(12):1382-91. PubMed ID: 11750096
[TBL] [Abstract][Full Text] [Related]
89. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
90. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Parry D; Peters G
Mol Cell Biol; 1996 Jul; 16(7):3844-52. PubMed ID: 8668202
[TBL] [Abstract][Full Text] [Related]
91. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds.
Hashemi J; Linder S; Platz A; Hansson J
Melanoma Res; 1999 Feb; 9(1):21-30. PubMed ID: 10338331
[TBL] [Abstract][Full Text] [Related]
92. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.
Byeon IJ; Li J; Ericson K; Selby TL; Tevelev A; Kim HJ; O'Maille P; Tsai MD
Mol Cell; 1998 Feb; 1(3):421-31. PubMed ID: 9660926
[TBL] [Abstract][Full Text] [Related]
93. Invasive melanoma in Cdk4-targeted mice.
Sotillo R; García JF; Ortega S; Martin J; Dubus P; Barbacid M; Malumbres M
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13312-7. PubMed ID: 11606789
[TBL] [Abstract][Full Text] [Related]
94. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
[TBL] [Abstract][Full Text] [Related]
95. The lncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence.
Montes M; Nielsen MM; Maglieri G; Jacobsen A; Højfeldt J; Agrawal-Singh S; Hansen K; Helin K; van de Werken HJG; Pedersen JS; Lund AH
Nat Commun; 2015 Apr; 6():6967. PubMed ID: 25908244
[TBL] [Abstract][Full Text] [Related]
96. Functional reassessment of P16 variants using a transfection-based assay.
Walker GJ; Gabrielli BG; Castellano M; Hayward NK
Int J Cancer; 1999 Jul; 82(2):305-12. PubMed ID: 10389768
[TBL] [Abstract][Full Text] [Related]
97. Germline mutations of the CDKN2 gene in UK melanoma families.
Harland M; Meloni R; Gruis N; Pinney E; Brookes S; Spurr NK; Frischauf AM; Bataille V; Peters G; Cuzick J; Selby P; Bishop DT; Bishop JN
Hum Mol Genet; 1997 Nov; 6(12):2061-7. PubMed ID: 9328469
[TBL] [Abstract][Full Text] [Related]
98. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model.
Kannan K; Sharpless NE; Xu J; O'Hagan RC; Bosenberg M; Chin L
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1221-5. PubMed ID: 12538879
[TBL] [Abstract][Full Text] [Related]
99. Genome-Wide Overexpression Screen Identifies Genes Able to Bypass p16-Mediated Senescence in Melanoma.
Lee WJ; Škalamera D; Dahmer-Heath M; Shakhbazov K; Ranall MV; Fox C; Lambie D; Stevenson AJ; Yaswen P; Gonda TJ; Gabrielli B
SLAS Discov; 2017 Mar; 22(3):298-308. PubMed ID: 27872202
[TBL] [Abstract][Full Text] [Related]
100. Genetic testing in hereditary melanoma.
Tsao H; Niendorf K
J Am Acad Dermatol; 2004 Nov; 51(5):803-8. PubMed ID: 15523363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
